GlaxoSmithKline PLC's majority-owned ViiV Healthcare is buying a raft of novel late-stage and early stage HIV assets from Bristol-Myers Squibb Co which it hopes will offer new options for patients who have outlived the utility of other antiretrovirals, thereby expanding ViiV's pipeline and future product sales.
GlaxoSmithKline PLC's majority-owned ViiV Healthcare is buying a raft of novel late-stage and early stage HIV assets from Bristol-Myers Squibb Co which it hopes will offer new options for patients who have outlived the utility of other antiretrovirals, thereby expanding ViiV's pipeline and future product sales.
As patients live longer and better with the HIV virus, many are outlasting the utility of various drugs and combination...
The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.
PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.
Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.
A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.
The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.
The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.
Series B cash will be used to advance its Stargardt disease gene therapy.
